ライフサイエンスコーパス: alopecia

1 xicity; more rash, pruritus, neuropathy, and alopecia).

2 as acne vulgaris, hirsutism, and androgenic alopecia.

3 phase of the hair cycle, resulting in cyclic alopecia.

4 ia totalis or alopecia universalis vs patchy alopecia.

5 nt scarring, disfiguration, and irreversible alopecia.

6 k late-stage disease with permanent scarring alopecia.

7 ged topical minoxidil therapy for androgenic alopecia.

8 for decades for the treatment of androgenic alopecia.

9 ndition we named enteropathy-lymphocytopenia-alopecia.

10 One hundred twenty-five (82%) reported alopecia.

11 lead to conditions such as aging-associated alopecia.

12 fe, his skin showed erosions, dry scale, and alopecia.

13 cular inflammation and widespread persistent alopecia.

14 for the treatment of hair disorders such as alopecia.

15 hair density, consistent with a nonscarring alopecia.

16 He did not have alopecia.

17 ride over the past 3 months for androgenetic alopecia.

18 ralgia, rash, photosensitivity, fatigue, and alopecia.

19 deficiency rickets even without evidence of alopecia.

20 en reentry decreases, leading to progressive alopecia.

21 the hair follicle plays a role in autoimmune alopecia.

22 ation in the nursing neonates, manifested as alopecia.

23 unctional, leading to HVDRR, with absence of alopecia.

24 ockout mice were viable but developed severe alopecia.

25 for leucopenia, neutropenia, infection, and alopecia.

26 signaling mediator, results in a progressive alopecia.

27 a hair follicle-cycling defect resulting in alopecia.

28 in and hair phenotype that emulates scarring alopecia.

29 sebum control and treatment of androgenetic alopecia.

30 n of the VDR, in humans and mice, results in alopecia.

31 ermal thickening, dermal cyst formation, and alopecia.

32 tor (VDR) mutations in humans and mice cause alopecia.

33 enting both IR- and cyclophosphamide-induced alopecia.

34 ged topical minoxidil therapy for androgenic alopecia.

35 Chemotherapy may induce alopecia.

36 lcium diet leads to transient noncicatricial alopecia.

37 to mothers fed a normal diet do not develop alopecia.

38 , low-calcium (0.47%) diet develop transient alopecia.

39 es such as psoriasis, atopic dermatitis, and alopecia.

40 , mainly represented by acne, hirsutism, and alopecia.

41 adhesions, defective follicle structure, and alopecia.

42 vel, low-risk therapeutic approach for scalp alopecias.

43 rops for glaucoma, may be relevant for scalp alopecias.

44 d to palmoplantar keratoderma and congenital alopecia-1, erythrokeratodermia variabilis et progressiv

45 had significantly fewer events of grade 1-4 alopecia (12 [10%] vs 42 [36%]) and peripheral neuropath

46 [26%] of 189), rash (19 [20%] vs 18 [10%]), alopecia (18 [19%] vs eight [4%]), and erythema (18 [19%

47 19%); hyperbilirubinemia (10% and 22%); and alopecia (18%).

48 Of those, 13 had reported no alopecia, 18 had reported moderate alopecia, and 11 had

49 rhoea (267 [57%] vs 111 [47%] patients), and alopecia (221 [47%] vs 125 [53%]).

50 enic disorders (182 [25%] vs 334 [47%]), and alopecia (23 [3%] vs 254 [36%]) were most common.

51 grades) included nausea (43% oral; 42% IV), alopecia (26% oral; 30% IV), fatigue (31% oral; 36% IV),

52 ns occurred in 6 patients (86%) and included alopecia (29%), dysgeusia (29%), muscle cramps (29%), an

53 findings, including cosmetically significant alopecia (30%), periorbital hyperpigmentation (30%), dee

54 most common were muscle spasms (317 [64%]), alopecia (307 [62%]), dysgeusia (269 [54%]), weight loss

55 peripheral edema (52.7%), diarrhea (35.4%), alopecia (33.9%), and nausea (33.3%).

56 le spasm (76%), followed by dysgeusia (57%), alopecia (47%), weight loss (47%) and decreased appetite

57 igue (50%), any peripheral neuropathy (50%), alopecia (49%), any rash (48%), decreased appetite (44%)

58 patients), neutropenia (79%), anemia (63%), alopecia (50%), elevated AST (50%), and constipation, na

59 emotherapy than with chemotherapy alone were alopecia (60 [74%] of 81 vs 44 [59%] of 75), nausea (56

60 nts), fatigue (82 [56%]), nausea (77 [52%]), alopecia (64 [44%]), conjunctivitis (63 [43%]), decrease

61 ot skin reaction (76.3%), diarrhoea (68.6%), alopecia (67.1%), and rash or desquamation (50.2%).

62 4%]), photosensitivity reaction (994 [31%]), alopecia (826 [26%]), and nausea (628 [19%]).

63 patients), weight loss (10), dysgeusia (9), alopecia (9), decreased appetite (5), and fatigue (4).

64 ciency, and, in some cases, autoimmunity and alopecia, a condition we named enteropathy-lymphocytopen

65 Other adverse events included hot flushes, alopecia, abdominal pain, and back pain.

66 ic myelogenous leukemia, reportedly produces alopecia according to the package insert, but clinical a

67 For those patients who reported alopecia, additional questions about reversal of hair lo

68 Androgenetic alopecia (AGA) is a common heritable and androgen-depend

69 Early androgenetic alopecia (AGA) is patterned hair loss occurring before a

70 ude that finasteride treatment of androgenic alopecia (AGA) is safe but do not assess quality of safe

71 Presence of androgenetic alopecia (AGA) might be such a predictor.

72 la cells (DPCs) taken from male androgenetic alopecia (AGA) patients undergo premature senescence in

73 Androgenetic alopecia (AGA), a hereditary disorder that involves the

74 Androgenetic alopecia (AGA), also known as common baldness, is charac

75 ential for the treatment of skin conditions (alopecia, allergic skin diseases, hyperpigmentation, pso

76 a (CCCA) is the most common form of scarring alopecia among women of African ancestry.

77 onsequence, the nursing neonates suffer from alopecia, anaemia and growth retardation owing to elevat

78 fore explored the association of early-onset alopecia and ALS in the Health Professionals Follow-up S

79 versus-host-like condition, characterized by alopecia and blepharitis.

80 ults, viable KRT8bc replacement mice develop alopecia and chronic skin lesions, indicating that the s

81 Restoration of Gsdma3 expression in AE (alopecia and excoriation) mouse skin rescues hair follic

82 n to bone marrow failure, he had evidence of alopecia and mucositis.

83 Alopecia and nail changes are not commonly reported side

84 Alopecia and nail changes were common adverse effects as

85 were eligible to complete a survey regarding alopecia and nail changes.

86 t Pparg(Delta/Delta) mice developed scarring alopecia and severe perifollicular inflammation.

87 cornifelin deficiency contributes to cyclic alopecia and skin abnormalities in Zdhhc13(skc4) mice.

88 hombencephalosynapsis with parietal/temporal alopecia and sometimes trigeminal anaesthesia, towering

89 vitamin D resistant rickets (HVDRR) without alopecia and successful management of this condition wit

90 s effective at reducing chemotherapy-induced alopecia and to assess adverse treatment effects.

91 ported no alopecia, 18 had reported moderate alopecia, and 11 had reported extensive alopecia at age

92 In addition to watery diarrhea, alopecia, and a complete loss of toenails and fingernail

93 hracycline regimens, longer-term measures of alopecia, and adverse effects.

94 lescence are telogen effluvium, androgenetic alopecia, and alopecia areata.

95 verse events with chemotherapy were fatigue, alopecia, and dyspnea.

96 thrombocytopenia, gastrointestinal symptoms, alopecia, and fatigue were the most common adverse event

97 kin, joint contractures, bone abnormalities, alopecia, and growth impairment in all 15 patients; card

98 on of this "toxic milk" causes inflammation, alopecia, and growth retardation in the nursing neonates

99 25; peripheral neuropathy, peripheral edema, alopecia, and nail disorders were more frequent with D75

100 FOXN1 deficiency leads to thymic aplasia, alopecia, and nail dystrophy, accounting for the nude/se

101 Rash, peripheral neuropathy, fatigue, alopecia, and nausea were the most common treatment-rela

102 diposity, decreased Scd-1 expression, facial alopecia, and osteoporosis.

103 ses severe phenotypes including amyloidosis, alopecia, and osteoporosis.

104 oliferative potential, stem cell exhaustion, alopecia, and premature aging.

105 resulting in cardiac hypertrophy, dwarfism, alopecia, and prenatal mortality.

106 Clinical features such as weight loss, alopecia, and skin ulcers, and histologic features with

107 associated with protection from early-onset alopecia, another sexually dimorphic condition.

108 syndrome combining linear hypopigmentation, alopecia, apparently asymptomatic leukoencephalopathy, a

109 clinical and histologic descriptions of the alopecia are lacking.

110 ostasis, the actions of the VDR that prevent alopecia are ligand-independent.

111 Because treatments for alopecia are not curative, helping affected patients cop

112 Acne and androgenic alopecia are prevalent but unreliable markers of biochem

113 We aimed to determine the risk of alopecia areata (AA) and vitiligo associated with atopic

114 Vitiligo and alopecia areata (AA) are common autoimmune conditions ch

115 Treatments for alopecia areata (AA) have evolved over the decades from

116 However, vitiligo and alopecia areata (AA) have not been well characterized in

117 t has long been appreciated that episodes of alopecia areata (AA) have occurred after severely stress

118 Alopecia universalis is an uncommon form of alopecia areata (AA) involving hair loss over the entire

119 Alopecia areata (AA) is a common autoimmune disease resu

120 Alopecia areata (AA) is a common T cell-mediated disorde

121 Alopecia areata (AA) is a genetically determined, immune

122 Alopecia areata (AA) is a non-scarring inflammatory hair

123 Alopecia areata (AA) is among the most highly prevalent

124 Alopecia areata (AA) is an autoimmune disease of the hai

125 Alopecia areata (AA) is an autoimmune disease that attac

126 Alopecia areata (AA) is an autoimmune disorder of the ha

127 Characterizing blood profile of alopecia areata (AA) is important not only for treatment

128 Alopecia areata (AA) is one of the most common forms of

129 fficiently investigated frontiers in current alopecia areata (AA) pathobiology research, with an emph

130 Alopecia areata (AA), a non-scarring inflammatory hair l

131 ) is increased in patients with vitiligo and alopecia areata (AA).

132 eg) cells was reported to play a key role in alopecia areata (AA).

133 ry skin diseases (atopic dermatitis [AD] and alopecia areata [AA]).

134 utpatients clinic, 2 to 16 years of age with alopecia areata affecting at least 10% of scalp surface

135 ese therapeutic techniques for patients with alopecia areata and further refine which subtypes of the

136 heumatic disease, thyroid disease, vitiligo, alopecia areata and inflammatory bowel disease) were sel

137 mice expressing this TCR develop spontaneous alopecia areata at nearly 100% incidence.

138 One patient with extensive alopecia areata experienced skin atrophy that resolved s

139 Few treatments for alopecia areata have been well evaluated in randomized t

140 characterize a new high-incidence model for alopecia areata in C57BL/6J mice, the first to our knowl

141 , a gene that is known to be associated with alopecia areata in humans.

142 a(+)NKG2D(+) T effector memory cells mediate alopecia areata in part through Janus kinase (JAK) signa

143 Alopecia areata is accompanied by Th2/Tc2 activation in

144 Alopecia areata is among the most prevalent autoimmune d

145 Alopecia areata is an idiopathic cause of hair loss with

146 Alopecia areata is an immune-mediated, nonscarring form

147 or efficacy of currently used treatments for alopecia areata is lacking.

148 Alopecia areata is less common, but may be distressing,

149 Alopecia areata is one of the most frequent organ-restri

150 y loci have been implicated, the genetics of alopecia areata is still unclear.

151 ating question regarding the pathogenesis of alopecia areata is the potential linkage with the brain.

152 hrough Janus kinase (JAK) signaling and that alopecia areata might be treated with JAK inhibitors.

153 In addition, although alopecia areata often results in significant psychologic

154 mon skin diseases, ranging from psoriasis to alopecia areata to vitiligo to lupus erythematosus to at

155 rticaria, pruritus, scabies, cellulitis, and alopecia areata were underrepresented in CDSR when match

156 (including psoriasis, atopic dermatitis, and alopecia areata) and eight other immune-mediated disease

157 be associated with Crohn disease, psoriasis, alopecia areata, and leprosy.

158 eczema, psoriasis, acne vulgaris, pruritus, alopecia areata, decubitus ulcer, urticaria, scabies, fu

159 the case of dermatological diseases such as alopecia areata, vitiligo, psoriasis and atopic dermatit

160 acne," "vitiligo," "seborrheic dermatitis," "alopecia areata," and "lichen planus." Diverse study pop

161 irst-line agent for limited patchy childhood alopecia areata.

162 a novel high-incidence model for spontaneous alopecia areata.

163 urrently being explored for the treatment of alopecia areata.

164 ivilege as a key step in the pathogenesis of alopecia areata.

165 a contributing factor in the development of alopecia areata.

166 elogen effluvium, androgenetic alopecia, and alopecia areata.

167 gs regarding the use of these treatments for alopecia areata.

168 ma, 0.03% for decubitus ulcer, and 0.01% for alopecia areata.

169 rthritis, juvenile idiopathic arthritis, and alopecia areata.

170 have a role in precipitating and maintaining alopecias as well.

171 ermine the prevalence and characteristics of alopecia associated with this agent.

172 rate alopecia, and 11 had reported extensive alopecia at age 45 years.

173 anges in the hair cycle underlie age-related alopecia, but the causative mechanisms have remained unc

174 was made to at least one form of cicatricial alopecia, but the role lipids play in other follicular p

175 benign prostatic hyperplasia and androgenic alopecia, but the role of 5alpha-dihydrotestosterone (DH

176 turization of hair follicles of androgenetic alopecia by interfering with the dermal papilla.

177 Primary cicatricial or scarring alopecias (CA) are a group of inflammatory hair disorder

178 arring alopecia resembling human cicatricial alopecias (CAs), particularly the central centrifugal CA

179 Central centrifugal cicatricial alopecia (CCCA) is the most common form of scarring alop

180 Chemotherapy-induced hair loss (alopecia) (CIA) remains a major unsolved problem in clin

181 calp cooling to prevent chemotherapy-induced alopecia, conclusions have been limited.

182 f starting therapy, although facial hair and alopecia continue to develop after 1 year.

183 Alopecia developed a mean (standard deviation) of 75 (54

184 Alopecia developed more commonly among TAC-treated patie

185 Alopecia development is associated with CD8(+) T cell ac

186 er treatment group (any grade) were fatigue, alopecia, diarrhoea, decreased appetite, and nausea.

187 ed exome sequencing in a group of women with alopecia (discovery set), compared the results with thos

188 oxicities were nausea, fatigue, neutropenia, alopecia, dizziness, and dyspnea.

189 ated adverse events included diarrhea, rash, alopecia, dry skin, and nausea.

190 eratinocytes and leads to the development of alopecia due to a defect in keratinocyte stem cells.

191 The alopecia, dwarfism and cardiac abnormalities were allevi

192 ore than 30% of patients were muscle spasms, alopecia, dysgeusia (taste disturbance), weight loss, an

193 oling devices have been used to prevent this alopecia, efficacy has not been assessed in a randomized

194 -WASP deficiency in mouse skin led to severe alopecia, epidermal hyperproliferation, and ulceration,

195 We show that the alopecia exhibited by both the Hoxc13(tm1Mrc) and Foxn1(

196 Frontal fibrosing alopecia (FFA) is a recently described inflammatory and

197 deficient mice had hypothyroidism, dwarfism, alopecia, goiter and cardiac abnormalities including hyp

198 v 1.4%), sensory neuropathy (4.1% v 0%), and alopecia (grade 1 or 2; 36.8% v 6.6%) occurred with PacC

199 Those who reported extensive alopecia had an almost 3-fold increased risk of ALS comp

200 gularly thickened interfollicular epidermis, alopecia, hair follicle dystrophy, claw dystrophy, and a

201 e tissue, reduced muscle strength, kyphosis, alopecia, hypothermia and shortened lifespan.

202 genome-wide association study for androgenic alopecia in 1,125 men and identified a newly associated

203 leads to a phenotype characterized by cyclic alopecia in addition to the dramatic skin and mucocutane

204 The most common forms of alopecia in adolescence are telogen effluvium, androgene

205 treatment, which causes chemotherapy-induced alopecia in mice and man, induces distinct defects in fe

206 y infiltrate, dysmorphic hair follicles, and alopecia in perinatal mice.

207 led to anemia, decreased growth, and truncal alopecia in pups which was restored following weaning.

208 s (66.3%; 95% CI, 56.2%-75.4%) evaluable for alopecia in the scalp cooling group vs 0 of 16 patients

209 oea, palmar-plantar erythrodysaesthesia, and alopecia in the sorafenib arm.

210 VDR-mediated PPARgamma suppression underlies alopecia in VDR(-/-) mice.

211 (VDR)-mediated PPARgamma suppression causes alopecia in VDR-null mice.

212 hat seen in primary cicatricial, or scarring alopecias in which immune targeting of hair follicle ste

213 emia" in gefitinib, erlotinib and afatinib, "alopecia"in erlotinib, "hair growth abnormal" in afatini

214 enzyme specifically in the epidermis causes alopecia, indicating that the regulation of RA homeostas

215 Alopecia, injection site erythema, and pruritus were 13%

216 ic myelogenous leukemia developed widespread alopecia involving scalp and body hair within weeks afte

217 Chemotherapy-induced alopecia is a common and distressing adverse effect.

218 Autoimmune alopecia is characterized by an extensive epidermal T ce

219 Understanding the impact of alopecia is important for care providers who see adolesc

220 Male pattern baldness (MPB) or androgenetic alopecia is one of the most common conditions affecting

221 mage determines whether chemotherapy-induced alopecia is reversible.

222 nciples and explain why chemotherapy-induced alopecia is so challenging to manage.

223 e (Propecia) for the treatment of androgenic alopecia is unknown.

224 vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, ph

225 bited palmoplantar keratosis and progressive alopecia, leading to alopecia totalis, associated with a

226 tion during postnatal development as well as alopecia, lethargy, and ataxia.

227 follicles, during the inflammatory permanent alopecia, lichen planopilaris.

228 or-like nutritional abnormalities, including alopecia, liver toxicity, and runting.

229 Androgenetic alopecia may begin in adolescence, and topical minoxidil

230 Hair loss, or alopecia, may occur as a primary skin disorder or becaus

231 the syndrome mandibulofacial dysostosis with alopecia (MFDA) who have de novo missense variants in ED

232 Using a murine autoimmune alopecia model, we observed an increase in early-activat

233 Mice homozygous for the juvenile alopecia mutation (jal) display patches of hair loss tha

234 mptoms (n = 9), mild stomatitis (n = 5), and alopecia (n = 4).

235 81 [48.8%]), back pain (n = 54 [32.5%]), and alopecia (n = 53 [31.9%]).

236 ripretinib 150 mg once daily (n = 142) were alopecia (n = 88 [62.0%]), fatigue (n = 78 [54.9%]), mya

237 more than 10% of administered doses included alopecia, neutropenia, fatigue, nausea, anemia, thromboc

238 r 15 normal subjects (5 females), and 2 with alopecia (non-functioning follicles).

239 d sporadic hair loss resembling the cyclical alopecia observed in mice with keratinocyte-specific del

240 Alopecia occurred in 2 subjects (reversed after stopping

241 rasae, epidermal expression does not lead to alopecia or other skin abnormalities typically seen in h

242 has a sevenfold-increased odds of androgenic alopecia (OR = 7.12, P = 3.7 x 10(-15)).

243 universalis compared with those with patchy alopecia (OR, 1.22; 95% CI, 1.01-1.48, P = .04).

244 The odds of having skin damage, alopecia, or diabetes were at least 5 times higher in Af

245 No grade > 1 nausea, vomiting, alopecia, or neuropathy events and no cardiac effects re

246 increased risk of congenital malformations, alopecia, or skin disorders.

247 rong biological phenotypes, including facial alopecia, osteoporosis, endoplasmic reticulum (ER) stres

248 epidermal stem cell compartments, results in alopecia owing to defective hair development.

249 of Dlx3 in the epidermis results in complete alopecia owing to failure of the hair shaft and inner ro

250 obiology of primary cicatricial ("scarring") alopecia (PCA) remains poorly understood and underinvest

251 In primary cicactricial alopecia (PCA), the hair follicle itself is the key targ

252 hea were more common with erlotinib; emesis, alopecia, peripheral neuropathy, and fatigue were more c

253 ease in bone density and entirely lacked the alopecia phenotype observed in age-matched Cbs(-/-) mice

254 parts in the degree of hair-follicle damage, alopecia phenotype, and hair-regrowth pattern.

255 illed in evaluating the most common forms of alopecia presenting in adolescence and should be aware o

256 undesired effects and risks including acne, alopecia, reduced HDL cholesterol, increased triglycerid

257 k of ALS compared with those who reported no alopecia (relative risk = 2.74, 95% confidence interval:

258 nagement strategies for chemotherapy-induced alopecia remain elusive.

259 Chemotherapy-induced alopecia represents one of the major unresolved problems

260 C57BL/6 mice develop dermatitis and scarring alopecia resembling human cicatricial alopecias (CAs), p

261 r fibroadiposis, palmoplantar keratosis, and alopecia, resembling the human cardiocutaneous syndromes

262 Cicatricial (scarring) alopecia results from irreversible damage to epithelial

263 egion in males with and without androgenetic alopecia revealed that next to the androgen receptor as

264 e-wide association studies on early balding (alopecia) revealed single nucleotide polymorphism varian

265 In conclusion, men with early-onset alopecia seem to have a higher risk of ALS.

266 ients), decreased appetite (nine [19%]), and alopecia (seven [15%]).

267 cterized by features of normal aging such as alopecia, skin wrinkling, and osteoporosis, patients wit

268 econdary end points included safety (with an alopecia-specific study) and overall survival (OS).

269 creased risks of prostate cancer, androgenic alopecia, spinal stenosis, and hypertension; and context

270 transgenic mice led to increased autoimmune alopecia susceptibility relative to nontransgenic litter

271 nimal model for at least some forms of focal alopecia that have their primary defect in the hair foll

272 hair follicles, linking the pathogenesis of alopecia to that of depigmentation disorders.

273 outcome was the evolution of the Severity of Alopecia Tool (SALT) score, evaluated by 2 independent i

274 audocephalic direction, resulting in truncal alopecia totalis by 20-23 days, with spontaneous recover

275 ies found higher odds of AD in patients with alopecia totalis or alopecia universalis compared with t

276 ed for childhood vs adult-onset vitiligo and alopecia totalis or alopecia universalis vs patchy alope

277 ially early-onset disease, or AA, especially alopecia totalis or alopecia universalis, have significa

278 y immunodeficiency characterized by athymia, alopecia totalis, and nail dystrophy.

279 ratosis and progressive alopecia, leading to alopecia totalis, associated with accelerated proliferat

280 d 4-10 years) with multiple scaly patches of alopecia underwent scalp dermoscopy, direct microscopic

281 s of AD in patients with alopecia totalis or alopecia universalis compared with those with patchy alo

282 IMPORTANCE Alopecia universalis is an uncommon form of alopecia are

283 en AA in patients.We report herein a case of alopecia universalis successfully treated with adalimuma

284 adult-onset vitiligo and alopecia totalis or alopecia universalis vs patchy alopecia.

285 sease, or AA, especially alopecia totalis or alopecia universalis, have significantly increased risk

286 chanism.OBSERVATIONS A woman in her 30s with alopecia universalis, refractory to multiple treatment m

287 s and regrowth, and ultimately progresses to alopecia universalis.

288 ents including Sjogren's syndrome, vitiligo, alopecia, uveitis, and others.

289 evere clinical symptoms, including diarrhea, alopecia, vasculitis, and fibrosis of the skin and visce

290 Further analysis revealed that the observed alopecia was likely the result of a progressive and ulti

291 Alopecia was more common in the DOX arm.

292 After course 1 of treatment, grade 3-4 alopecia was reported in 23 (23%) of 98 patients in the

293 After course 2 of treatment, grade 3-4 alopecia was reported in 25 (28%) of 89 patients in the

294 molecular mechanisms of Smad4 loss-mediated alopecia, we examined expression levels of key molecules

295 e (end-stage scarring), and controls with no alopecia were also studied.

296 dverse effects such as nausea, vomiting, and alopecia were more common with CMF, whereas symptoms of

297 ces of peripheral neuropathy/paresthesia and alopecia were significantly higher in patients treated w

298 cal toxicities (mild enophthalmos and eyelid alopecia) were observed only at the highest dose tested

299 g striking resemblance to irreversible human alopecia, which also displays reduced NFIs.

300 He was on treatment for androgenic alopecia with topical 5% Minoxidil application on scalp